GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members…
In a groundbreaking study published recently in Nature Communications, researchers have delved into the intricate immune mechanisms responsible for the development of immunotherapy-induced pneumonitis in lung cancer patients. This research…
In a groundbreaking study published in the Journal of Perinatology, researchers have unveiled intricate connections between the nucleated red blood cell (NRBC) count at birth, red blood cell (RBC) transfusion…
A groundbreaking new study has uncovered alarming levels of metallic contamination associated with plastic litter found along the shores of South Africa’s Table Bay, specifically at Woodbridge Island and Derdesteen.…
In the realm of healthcare, the importance of timely service cannot be overstated. As populations grow and healthcare demands increase, hospitals and clinics face unprecedented challenges. Among these challenges, outpatient…
In the realm of neurodegenerative diseases, the understanding of Lewy body diseases and other alpha-synucleinopathies has rapidly evolved, with significant focus placed on the identification of biomarkers in biofluids. The…
Cleary joins Restore as the company accelerates its clinical pathway toward advanced US studies , /PRNewswire/ — Restore Medical Ltd., a privately held medical device company developing a novel transcatheter…
RAMAT GAN, Israel, Nov. 26, 2025 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs targeting oncological…
BOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Adam Crystal, M.D., Ph.D., President of Research & Development at Tango Therapeutics, is scheduled to…
NEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced…